Long-Term Real-World Post-approval Safety Data of Multiple Biosimilars from One Marketing-Authorization Holder After More than 18 Years Since Their First Biosimilar Launch-Reference-Cited by-同舟云学术

Long-Term Real-World Post-approval Safety Data of Multiple Biosimilars from One Marketing-Authorization Holder After More than 18 Years Since Their First Biosimilar Launch

Published:2023-10-30 Issue:12 Volume:46 Page:1391-1404
ISSN:0114-5916
Container-title:Drug Safety
language:en
Short-container-title:Drug Saf

Author:

Sagi Sreedhar^ORCID,Anjaneya Pradeep,Kalsekar Sameer,Kottke Andrea,Cohen Hillel P.^ORCID

Funder

Sandoz International GmBH

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Toxicology

Link

https://link.springer.com/content/pdf/10.1007/s40264-023-01371-8.pdf

Reference32 articles.

1. Biosimilars in the EU. Information guide for healthcare professionals. Prepared jointly by the European Medicines Agency and the European Commission. Biosimilars in the EU - Information guide for healthcare professionals (www.europa.eu). Accessed 31 Aug 2023.

2. Healthcare expenditure statistics. Eurostat, Statistics Explained. Healthcare expenditure statistics - Statistics Explained (www.europa.eu). Accessed 31 Aug 2023.

3. Biosimilar and Interchangeable Biologics: More Treatment Choices. U.S. Food & Drug Administration. https://www.fda.gov/consumers/consumer-updates/biosimilar-and-interchangeable-biologics-more-treatment-choices#:~:text=Biosimilar%20and%20Interchangeable%20Biologics%3A%20More%20Treatment%20Choices%201,and%20Effective%20...%203%20Interchangeable%20Biosimilar%20Medications%20. Accessed 31 Aug 2023.

4. Guideline on similar biological medicinal products. Committee for Medicinal Products for Human Use (CHMP). European Medicines Agency. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-rev1_en.pdf. Accessed 31 Aug 2023.

5. Kurki P, Kang HN, Ekman N, et al. Regulatory evaluation of biosimilars: Refinement of principles based on the scientific evidence and clinical experience. BioDrugs. 2022;36:359–71. https://doi.org/10.1007/s40259-022-00533-x.